酪氨酸激酶抑制剂时代的细胞减灭性肾切除术：一个可能永远无法回答的问题。
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
机构信息
Academic Urology Group, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Royal Free Hospital, London, UK.
出版信息
Eur Urol. 2017 Jun;71(6):845-847. doi: 10.1016/j.eururo.2016.10.029. Epub 2016 Nov 1.
Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
尽管人们非常感兴趣，但在转移性肾细胞癌的酪氨酸激酶抑制剂治疗中进行的两次细胞减灭性肾切除术的随机对照试验（RCT）要么提前关闭（SURTIME），要么在 7 年后招募速度非常缓慢（CARMENA）。在泌尿肿瘤外科中进行 RCT 交付存在诸多挑战。为解决重要的泌尿外科癌症问题而进行的 RCT 需要多个步骤来确保强有力的招募。可行性/试验性研究是成功开展外科 RCT 的关键垫脚石。
Zotero 插件